Who is sponsoring NCT05745610?

NCT05745610 is sponsored by Zhongnan Hospital.

What drugs are being tested in NCT05745610?

Interventions in NCT05745610: Shen Hai Long Capsule, Sheng Jing Capsule.

Is NCT05745610 still recruiting?

NCT05745610 is currently status unknown. Last updated 27 February 2023.

Last reviewed 2023-02-27 · How we verify

NCT05745610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shen Hai Long Capsule for Male Asthenospermia

Status unknown NA Last updated 27 February 2023

What this trial tests

NA trial testing Shen Hai Long Capsule in Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men in 120 participants. Status unknown.

Timeline

15 February 2023

Primary endpoint
30 June 2024

31 December 2024

Quick facts

Lead sponsor	Zhongnan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	15 February 2023
Primary completion	30 June 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Shen Hai Long Capsule — full drug profile →
Sheng Jing Capsule — full drug profile →

Conditions studied

Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men — all drugs for Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men →

Sponsor

Zhongnan Hospital

Who can join

Adults 22 to 50, male only, with Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Zhongnan Hospital trials

Trials by the same sponsor.

NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05745610 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
Last refreshed: 27 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing